

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.		
10/728,340	12/04/2003	Dale M. Edgar	3561.1000-007	8597	
75	90 06/06/2006		EXAMINER		
Ivor R. Elrifi, Esq.			CHANG, CELIA C		
Mintz, Levin, C One Financial C	ohn, Ferris, Glovsky & Po Center	opeo, P.C.	ART UNIT PAPER NUMBER 1625 DATE MAILED: 06/06/2006		
Boston, MA 0	2111				

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/728,340	EDGAR ET AL.	
Office Action Summary	Examiner	Art Unit	
	Celia Chang	1625	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	ldress
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this co O (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on <u>06 M</u> . This action is FINAL . 2b)⊠ This Since this application is in condition for allowar closed in accordance with the practice under E.	action is non-final. nce except for formal matters, pro		e merits is
Disposition of Claims			
4) ⊠ Claim(s) <u>1-17</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>1-12</u> is/are rejected. 7) ⊠ Claim(s) <u>13-17</u> is/are objected to. 8) □ Claim(s) are subject to restriction and/or	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	: 37 CFR 1.85(a). ected to. See 37 CF	• •
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No Id in this National	Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	te	D-152)

Application/Control Number: 10/728,340 Page 2

Art Unit: 1625

DETAILED ACTION

1. Applicant's election without traverse of group I, claims 7-17 in the reply filed on Mar. 6, 2006 is acknowledged.

Claims 7-17 are prosecuted together with claims 1-6 reading on X1 is O. The remaining subject matter in claims 1-6 are withdrawn from consideration.

2. Applicant is reminded of the proper content of an Abstract of the Disclosure.

In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." Exemplification of a species could be illustrative of members of the class. For processes, the type reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary.

Revision of the abstract to include structure of compounds and composition is required.

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1625

Claims 1-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ito et al. US 5,095,022.

Determination of the scope and content of the prior art (MPEP §2141.01)

Ito et al. '022 disclosed CNS compounds having similar structure as the claims. See examples 4-40.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

The difference between the instant claims and the prior art compounds is that instead of alkylene linker as spacer, the claims are drawn to lower alkyl substituted alkylene linker. Generically, Ito et al. taught that the alkylene linker as the "Y" moieties could be unsubstituted or optionally substituted with lower alkyl (see col. 2 lines 35-37).

Finding of prima facie obviousness—rational and motivation (MPEP§2142-2143)

One having ordinary skill in the art in possession of the Ito '022 reference would be in possession of the claimed substituted alkylene linker compounds **because** Ito '022 exemplified variations of alkylene chains (see example 4-40) with clear teaching that lower alkyl substitution of such alkylene chain would be expected to have similar activity as the unsubstituted chain compounds. In absence of unexpected result, it is prima facie obvious to choose some among many. In re Lemin 141 USPO 841.

4. Claims 13-17 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The substitution of the alkylene spacer by cyclic substituent or heteroatom has not been disclosed or fairly suggested by the art of record.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas McKenzie, Ph. D., can be reached on 571-272-0670. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/728,340 Page 4

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang May 24, 2006 Celia Chang

Primary Examiner

Art Unit 1625